HLA-B*5701 screening for hypersensitivity to abacavir.
By S. Mallal, E. Phillips, G. Carosi, J. Molina, C. Workman, J. Tomažič, E. Jägel-Guedes, S. Rugina, O. Kozyrev, J. Cid and 8 more. New England Journal of Medicine, 2008
1,635 citations recorded by the source corpus.
Subfields: Dermatology, Immunology and Allergy, Pharmacology
View Paper: https://www.semanticscholar.org/paper/524d37bdd0de59c3af3e63ca4fe23236fb661dac
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pharmacology
Citations in the corpus
- Extracting research-quality phenotypes from electronic health records to support precision medicine (2015, background): “These centers have shown that genomic data can be used to tailor prescribing decisions to target therapies better [146,147] and to avoid serious drug adverse events [148,149], which are often impossible to predict without using genetics.”
- Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. (2008, background): “The Prospective Randomized Evaluation of DNA Screening in a Clinical Trial (PREDICT) study demonstrated the clinical value of prospective HLAB*5701 screening to identify patients at risk of abacavir-associated hypersensitivity reaction (HSR).(84) Those screening negative for HLA-B*5701 rarely develo”
- Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. (2013, methodology): “HLA-B5701 is used to identify patients infected with human immunodeficiency virus (HIV) at risk for abacavir hypersensitivity [62], and IL-28B genotype may predict the clinical efficacy of in-”
- International Consensus on drug allergy (2014, background): “and is mandatory before starting treatment 1++ A (47)”
- Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action (2012, background): “…underlying mechanism is not fully understood include patients with variants in major histocompatibility complex class IB (HLA-B*5701) who show hypersensitivity to the antiviral drug abacavir (43) and musculoskeletal toxicity from aromatase inhibitors used to treat breast and ovarian cancers (44).”